HCPLive Endocrinology

Check out this interview and use the link below for more #ESCCongress content: https://lnkd.in/eQ8CwJQF

The Dexcom Stelo now available at Stelo.com. Learn more about pricing and features in the article on HCPLive:

ICYMI: In a recent #DiabetesDialogue, Muthu Vaduganathan, MD, MPH of Brigham and Women's Hospital, discusses what we know so far about the FINEARTS-HF trial and what he is looking forward to from #ESCCongress with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, of Cleveland Clinic, and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES, of University Hospitals. Learn more: https://lnkd.in/eJc88mMs #HeartFailure

Today, Rivus Pharmaceuticals announced the Phase 2a HuMAIN clinical trial of HU6 met its primary endpoint of weight loss. In the trial, HU6 demonstrated statistically significant weight reduction in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Read more on the announcement here: https://lnkd.in/ev234WRJ #ObesityManagement #HeartFailure

Another new episode of #DiabetesDialogue Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES are joined by Muthu Vaduganathan, MD, MPH, of Brigham and Women's Hospital, for a discussion on the latest updates in HFpEF! Vaduganathan, a trial investigator for FINEARTS-HF and co-host of HCPLive Cardiology's Don't Miss a Beat podcast, sheds light on recent developments in heart failure, namely topline data announcements from the SUMMIT (tirzepatide; Eli Lilly and Company) and FINEARTS-HF (finerenone; Bayer trials. Check out the preview and use the link below for the full episode! https://lnkd.in/eJc88mMs #HeartFailure #HFpEF #ESC2024

Learn more about the Medtronic Simplera continuous glucose monitor as well as Medtronic's new partnership with Abbott in the latest episode of #DiabetesDialogue.

The latest edition of the Provider's Digest, HCPLive's monthly newsletter spotlighting regulatory decisions and pipeline news, is now live! In our July 2024 recap, we spotlight 9 FDA decisions, 6 submissions or new designations, and 5 topline data announcements. Be sure to subscribe for a recap of the therapies, companies, and individuals moving the needle in healthcare during the past month, delivered on the first Saturday of each new month! #FDANews #Healthcare #Medicine

Major news from the incretin therapy pipeline!

Article of the Week: An analysis from Cedars-Sinai using records from 40 million US patients in the TriNetX database highlights the surge in new GLP-1 receptor agonist use, with semaglutide dominating new prescriptions since 2020.

New data and advances have transformed conversations around management of #ChronicKidneyDisease, begging the question: Is it time to discuss combination therapy approaches? Hear from Brendon L Neuen, MBBS, PhD, of The George Institute for Global Health, on recent data from the SMART-C consortium and what is next for #nephrology:  https://lnkd.in/e58DuXBe